Hi, doc. Thanks for responding. It also seems that these tweets are an attempt to highlight the difference between potential treatment through Ii-key and those from J&J, PFE, and MRNA. Do you have any sense if Generex is setting up some kind of major introduction of Ii-key, or this just run of the mill fluff and hope?